Certara (NASDAQ:CERT) Issues FY 2026 Earnings Guidance

Key Points

• Certara guided to FY 2026 EPS of $0.31–$0.34, versus the $0.31 consensus, and revenue of $427.2 million–$431.4 million, well above the $380.9 million estimate.
• In its latest quarter, Certara reported EPS of $0.09, matching forecasts, and revenue of $94.9 million, above estimates of $92.01 million; revenue was down 9.3% year over year.
• Shares rose $1.09 to $12.18 in Thursday mid-day trading. Analysts’ average rating was “Hold,” with an average price target of $9.18.

Certara (NASDAQ:CERT - Get Free Report) issued an update on its FY 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 0.310-0.340 for the period, compared to the consensus earnings per share estimate of 0.310. The company issued revenue guidance of $427.2 million-$431.4 million, compared to the consensus revenue estimate of $380.9 million.

Certara Price Performance

Shares of CERT traded up $1.09 during mid-day trading on Thursday, reaching $12.18. The stock had a trading volume of 3,731,632 shares, compared to its average volume of 3,405,488. The business has a fifty day moving average of $9.18 and a 200 day moving average of $7.32. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.55 and a current ratio of 2.55. The firm has a market cap of $1.86 billion, a price-to-earnings ratio of -27.07 and a beta of 1.30. Certara has a 12 month low of $4.45 and a 12 month high of $12.25.

Certara (NASDAQ:CERT - Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported $0.09 EPS for the quarter, hitting the consensus estimate of $0.09. Certara had a negative net margin of 16.75% and a positive return on equity of 3.86%. The business had revenue of $94.90 million for the quarter, compared to analysts' expectations of $92.01 million. During the same quarter in the previous year, the company earned $0.14 EPS. The business's quarterly revenue was down 9.3% compared to the same quarter last year. Certara has set its FY 2026 guidance at 0.310-0.340 EPS. Equities analysts predict that Certara will post 0.21 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on CERT shares. KeyCorp raised their target price on shares of Certara from $9.00 to $12.00 and gave the company an "overweight" rating in a report on Friday, October 16th. Weiss Ratings cut Certara from a "sell (d)" rating to a "sell (d-)" rating in a research note on Thursday, October 8th. TD Cowen boosted their target price on Certara from $9.00 to $11.00 and gave the company a "buy" rating in a research report on Tuesday, October 13th. UBS Group cut shares of Certara from a "buy" rating to a "neutral" rating and set a $10.00 price objective on the stock. in a research report on Wednesday, September 30th. Finally, Barclays upped their price target on shares of Certara from $7.50 to $9.00 and gave the company an "equal weight" rating in a report on Wednesday, October 7th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Certara presently has an average rating of "Hold" and an average price target of $9.18.

Certara Company Profile

Certara is a global provider of software and services that support drug development and regulatory approval. The company helps biopharmaceutical and pharmaceutical organizations use quantitative methods, modeling and simulation, and regulatory science to improve decisions throughout the development process.

Its software portfolio includes platforms for pharmacometric modeling and simulation, clinical trial design and analysis, pharmacology and safety assessment, data visualization, and regulatory submission management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.